Yubo Intl Biotech A (YBGJ) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 29, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q2 FY2026, filed Aug 14, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the YBGJ SEC filings page.
Yubo Intl Biotech Ltd A (YBGJ) reported $12K in revenue for fiscal year 2025, up 256.0% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
FY2025 combines a tiny revenue base of $12K with a $1.1M net loss, leaving financing to support operations.
The cash-funding pattern is the key: FY2025 operating cash flow was-$843K while financing cash flow was$850K , so outside funding almost offset the cash consumed by operations. Meanwhile, liabilities were329.5% of assets and the current ratio was 0.2x, indicating obligations exceed asset backing and near-term resources are thin.
Revenue rebounded from
The balance sheet structure remains heavily burdened: liabilities were
Financial Health Signals
We do not publish a peer-relative financial health score for Yubo Intl Biotech Ltd A, because the score only covers companies whose filings and listing give us what it needs to compare them with their peers. The signals and metrics below are current.
Yubo Intl Biotech Ltd A scores -20.22, below the 1.81 distress threshold. The score is pulled down most by an accumulated deficit of $7.7M against total assets of $847K. This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Yubo Intl Biotech Ltd A passes 3 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 1 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass, 1 of 2 operating efficiency signals passes.
Yubo Intl Biotech Ltd A reported a net loss of $1.1M while operations used $843K of cash. With neither figure positive, the ratio between the two carries no quality signal.
Yubo Intl Biotech Ltd A reported an operating loss of $1.2M against $243 in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
Yubo Intl Biotech Ltd A generated $0 in revenue in Q2 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Yubo Intl Biotech Ltd A's EBITDA was -$238K in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Yubo Intl Biotech Ltd A reported a net loss of $248K in Q2 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Yubo Intl Biotech Ltd A earned $0.00 per diluted share (EPS) in Q2 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Cash & Balance Sheet
Yubo Intl Biotech Ltd A held $12K in cash as of Q2 2026; no long-term debt figure is on record for that period.
Not reported for Q2 2026.
Not reported for Q2 2026.
Margins & Returns
None of these metrics is reported for Q2 2026.
Capital Allocation
None of these metrics is reported for Q2 2026.
YBGJ Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0n/m | $0n/m | $12K | $0n/m | $0n/m | $0-100.0% | N/A | $0-100.0% |
| Cost of Revenue | $0n/m | $0n/m | $4K | $0n/m | $0n/m | $0-100.0% | N/A | $0-100.0% |
| Gross Profit | $0n/m | $0n/m | $8K | $0n/m | $0n/m | $0-100.0% | N/A | $0-100.0% |
| Operating Income | -$239Kn/m | -$289Kn/m | N/A | -$310Kn/m | -$250Kn/m | -$467Kn/m | N/A | -$533K-8394.6% |
| EBITDA | -$238Kn/m | -$264Kn/m | N/A | -$268Kn/m | -$208Kn/m | -$426Kn/m | N/A | -$487K-1061.4% |
| Interest Expense | N/A | N/A | N/A | $18-63.3% | $23+35.3% | N/A | N/A | $49-62.3% |
| Income Tax | $0n/m | $0n/m | $0 | $0n/m | $0n/m | $0n/m | N/A | $0n/m |
| Net Income | -$248Kn/m | -$273Kn/m | N/A | -$310Kn/m | -$230Kn/m | -$436Kn/m | N/A | -$621K-9968.9% |
| EPS (Diluted) | $0.00n/m | $0.00n/m | $0.00n/m | $0.00n/m | $0.00n/m | $0.00 | -$0.01 | -$0.01n/m |
| Diluted Shares (Avg) | 170M+42.2% | 170M+42.2% | N/A | 148M+23.4% | 120M0.0% | 120M | N/A | 120M0.0% |
Not reported in any period shown, so not listed: R&D Expenses, SG&A Expenses, EPS (Basic).
YBGJ Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $672K-36.1% | $710K-39.1% | $847K-44.8% | $953K-42.4% | $1.1M-39.2% | $1.2M-24.7% | $1.5M-7.9% | $1.7M-13.1% |
| Current Assets | $583K-11.5% | $598K-12.7% | $668K-2.2% | $650K-10.3% | $659K-13.4% | $685K-6.8% | $683K-5.9% | $724K+1.6% |
| Cash & Equivalents | $12K+15.1% | $10K+6.2% | $8K+14.9% | $11K+36.0% | $10K+35.3% | $10K-82.9% | $7K+10.3% | $8K+51.7% |
| Short-Term Investments | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m |
| Inventory | $25K-34.1% | $24K-34.4% | $24K-35.0% | $38K+476.3% | $38K-56.7% | $37K-82.4% | $37K-82.8% | $7K-96.9% |
| Long-Term Investments | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m |
| Total Liabilities | $3.3M-33.9% | $3.0M-37.3% | $2.8M-42.2% | $2.6M-45.6% | $5.0M+21.3% | $4.8M+33.3% | $4.8M+37.6% | $4.7M+56.3% |
| Current Liabilities | $3.3M-33.8% | $3.0M-36.9% | $2.8M-40.9% | $2.6M-43.1% | $5.0M+27.1% | $4.8M+35.9% | $4.7M+39.1% | $4.5M+56.7% |
| Non-Current Liabilities | $0-100.0% | $0-100.0% | $0-100.0% | $0-100.0% | $8K-96.0% | $31K-66.0% | $111K-4.1% | $206K+47.8% |
| Total Equity | -$2.6Mn/m | -$2.3Mn/m | -$2.0Mn/m | -$1.7Mn/m | -$4.0Mn/m | -$3.7Mn/m | -$3.4Mn/m | -$3.1Mn/m |
| Retained Earnings | -$8.3Mn/m | -$8.0Mn/m | -$7.7Mn/m | -$7.5Mn/m | -$7.3Mn/m | -$7.1Mn/m | -$6.7Mn/m | -$6.4Mn/m |
Not reported in any period shown, so not listed: Accounts Receivable, Goodwill, Long-Term Debt.
YBGJ Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$84Kn/m | -$207Kn/m | -$129Kn/m | -$308K-187.2% | -$14Kn/m | -$392Kn/m | -$933Kn/m | $353K+6860.7% |
| Depreciation & Amortization | $793-98.1% | $26K-38.1% | $43K+9.0% | $42K-8.9% | $42K+0.8% | $42K-3.9% | $39K-65.0% | $46K+4.0% |
| Capital Expenditures | N/A | $0-100.0% | N/A | N/A | N/A | $6K-67.3% | N/A | N/A |
| Free Cash Flow | N/A | -$207Kn/m | N/A | N/A | N/A | -$398Kn/m | N/A | N/A |
| Investing Cash Flow | $0-100.0% | $0n/m | -$80Kn/m | $0-100.0% | $86K-23.1% | -$6Kn/m | $0n/m | $36Kn/m |
| Financing Cash Flow | $77K-60.6% | $215K-22.8% | $376K-66.1% | $0n/m | $196K-52.2% | $278K-9.9% | $1.1M+48.8% | -$421Kn/m |
Not reported in any period shown, so not listed: Stock-Based Compensation, Dividends Paid, Share Buybacks.
YBGJ Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | 66.1% | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | -36.9%-15.0pp | -38.4%-1.1pp | N/A | -32.5%+5.0pp | -21.9%+8.6pp | -37.4%-13.0pp | N/A | -37.5%-37.9pp |
| Current Ratio | 0.180.0x | 0.20+0.1x | 0.24+0.1x | 0.25+0.1x | 0.13-0.1x | 0.14-0.1x | 0.14-0.1x | 0.16-0.1x |
| Asset Turnover | 0.000.0x | 0.000.0x | 0.01 | 0.000.0x | 0.000.0x | 0.000.0x | N/A | 0.00-0.2x |
Not reported in any period shown, so not listed: Operating Margin, Net Margin, Return on Equity, Debt-to-Equity, Liabilities-to-Equity, FCF Margin.
Note: Shareholder equity is negative (-$2.0M), which causes the debt-to-equity, liabilities-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Note: The current ratio is below 1.0 (0.24), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it. Market cap is stated at each company's latest close.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Yubo Intl Biotech Ltd A YBGJ | FY2025 | $12K | -$1.1M | N/A | $920K | — |
| Encision Inc ECIA | FY2025 | $6.6M | -$220K | -3.4% | $566K | — |
Where Yubo Intl Biotech Ltd A Ranks
Frequently Asked Questions
Yubo Intl Biotech Ltd A (YBGJ) reported $12K in total revenue for fiscal year 2025. This represents a 256.0% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
Yubo Intl Biotech Ltd A (YBGJ) revenue grew by 256.0% year-over-year, from $3K to $12K in fiscal year 2025.
No, Yubo Intl Biotech Ltd A (YBGJ) reported a net loss of $1.1M in fiscal year 2025.
Yubo Intl Biotech Ltd A (YBGJ) had EBITDA of -$1.0M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
Yubo Intl Biotech Ltd A (YBGJ) had a gross margin of 66.1% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
Yubo Intl Biotech Ltd A (YBGJ) recorded an outflow of $843K in operating cash flow during fiscal year 2025, representing cash used by core business activities.
Yubo Intl Biotech Ltd A (YBGJ) had $847K in total assets as of fiscal year 2025, including both current and long-term assets.
Yubo Intl Biotech Ltd A (YBGJ) had a current ratio of 0.24 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.
Yubo Intl Biotech Ltd A (YBGJ) had a return on assets of -127.4% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
Yubo Intl Biotech Ltd A (YBGJ) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2025). The market capitalization is $920K as of Oct 29, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
Yubo Intl Biotech Ltd A (YBGJ) trades at 74.5x sales, its market capitalization divided by $12K revenue, trailing 12 months to June 30, 2026. The market capitalization is $920K as of Oct 29, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
At the end of fiscal year 2025, Yubo Intl Biotech Ltd A (YBGJ) held $8K in cash, cash equivalents and investments, and reported an operating cash outflow of $843K over that year. Dividing the one by the other, the reported balance equals about 0 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
Yubo Intl Biotech Ltd A (YBGJ) has negative shareholder equity of -$2.0M as of fiscal year 2025, so no debt-to-equity or liabilities-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.
Yubo Intl Biotech Ltd A (YBGJ) has an Altman Z-Score of -20.22, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
Yubo Intl Biotech Ltd A (YBGJ) has a Piotroski F-Score of 3 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Yubo Intl Biotech Ltd A (YBGJ) reported a net loss of $1.1M while operations used $843K of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Yubo Intl Biotech Ltd A (YBGJ) reported an operating loss of $1.2M against $243 in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.